Phase II trial shows drug combination promising in advanced melanoma
the ONA take:
Clinical trial shows simultaneous administration of ipilimumab and nivolumab produced better treatment response in patients with advanced melanoma who had received no prior treatment.
The phase II, double-blind trial enrolled 142 patients with advanced melanoma who had not received prior treatments. The patients were randomly assigned to receive ipilimumab plus nivolumab followed by nivolumab alone or ipilimumab plus placebo followed by placebo alone.
The ipilimumab-nivolumab combination produced an overall response rate of 60% in the 109 patients without BRAF mutations, including 17% complete response and 43% partial response rates.
The ipilimumab-placebo combination resulted in overall response rate of 11%, with no complete responses and 11% partial response rate.
Among the 33 patients with BRAF V600 mutations, overall response rate was 44%, including 17% complete response and 26% partial response rates.
Ipilimumab and nivolumab produced better treatment response in patients with advanced melanoma who had received no prior treatment.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|